Results 11 to 20 of about 51,741 (305)

BNT162b2 mRNA COVID-19 Vaccine: First Approval [PDF]

Drugs, 2021
BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Yvette N. Lamb
openaire   +3 more sources

Waning Immunity after the BNT162b2 Vaccine in Israel

New England Journal of Medicine, 2021
In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021.
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman, Eric J. Haas, Ron Milo, Sharon Alroy-Preis, Nachman Ash, Amit Huppert   +9 more
openaire   +3 more sources

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization [PDF]

Nature, 2021
Abstract The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections 1 .
Sandile Cele, Laurelle Jackson, David S. Khoury, Khadija Khan, Thandeka Moyo-Gwete, Houriiyah Tegally, James Emmanuel San, Deborah Cromer, Cathrine Scheepers, Daniel G. Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett I. Gosnell, Salim S. Abdool Karim, Willem Hanekom, Mary-Ann Davies, Marvin Hsiao, Darren Martin, Koleka Mlisana, Constantinos Kurt Wibmer, Carolyn Williamson, Denis York, Rohen Harrichandparsad, Kobus Herbst, Prakash Jeena, Thandeka Khoza, Henrik Kløverpris, Alasdair Leslie, Rajhmun Madansein, Nombulelo Magula, Nithendra Manickchund, Mohlopheni Marakalala, Matilda Mazibuko, Mosa Moshabela, Ntombifuthi Mthabela, Kogie Naidoo, Zaza Ndhlovu, Thumbi Ndung’u, Nokuthula Ngcobo, Kennedy Nyamande, Vinod Patel, Theresa Smit, Adrie Steyn, Emily Wong, Anne von Gottberg, Jinal N. Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, Miles P. Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal   +60 more
openaire   +6 more sources

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age [PDF]

New England Journal of Medicine, 2022
Background: Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.Methods: A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to ...
Barnett, E. D., Belanger, T. J., Cooper, D., Cunliffe, L., Domachowske, J. B., Dormitzer, P. R., Frenck, R. W., Jr., Gruber, W. C., Gurtman, A., Jansen, K. U., Kitchin, N., Koury, K., Kuchar, E., Lagkadinou, E., Lockhart, S., Ma, H., Maldonado, Y., Mather, S., Munjal, I, Munoz, F. M., Pahud, B. A., Paulsen, G. C., Perez, J. L., Rojo, P., Rämet, M., Sabharwal, C., Sarwar, U. N., Simoes, E. A. F., Swanson, K. A., Talaat, K. R., Tureci, O., Walter, E. B., Xu, X.   +32 more
core   +2 more sources

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 [PDF]

Nature Medicine, 2021
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 ...
Joseph E. Ebinger, Justyna Fert‐Bober, Ignat Printsev, Min Wu, Nancy Sun, John C. Prostko, Edwin C. Frias, James L. Stewart, Jennifer E. Van Eyk, Jonathan Braun, Susan Cheng, Kimia Sobhani   +11 more
openalex   +2 more sources

Beyond neutralization for BNT162b2 mRNA vaccination [PDF]

Cell Host & Microbe, 2021
Mounting a robust immune response against SARS-CoV-2 requires neutralization as well as effector T cell functions. In this issue of Cell Host Microbe, Tauzin et al. characterize the humoral and T cell responses after a single dose of BNT162b2 mRNA vaccine in individuals with or without previous exposure to SARS-CoV-2.
Damani-Yokota, Payal, Yeung, Stephen T., Khanna, Kamal M.   +2 more
openaire   +2 more sources

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Vaccines, 2022
Emerging numbers of SARS-CoV-2 infections are currently combated with a third vaccination. Considering the different vaccination regimens used for the first two vaccine doses, we addressed whether the previous vaccination influences the immune response to the booster. Participants for this prospective study were recruited from among healthcare workers.
Rieke Reiter, Pia Von Blanckenburg, Reinier Mutters, Julia Thiemer, Reinhard Geßner, Ulf Seifart   +5 more
openaire   +4 more sources

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

New England Journal of Medicine, 2021
Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting.
Noa Dagan, N. Barda, Eldad Kepten, O. Miron, Shay Perchik, M. Katz, M. Hernán, M. Lipsitch, B. Reis, R. Balicer   +9 more
semanticscholar   +1 more source

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

New England Journal of Medicine, 2021
Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel.
Einav G. Levin, Y. Lustig, Carmit Cohen, R. Fluss, V. Indenbaum, S. Amit, R. Doolman, K. Asraf, E. Mendelson, A. Ziv, Carmit Rubin, L. Freedman, Y. Kreiss, G. Regev-Yochay   +13 more
semanticscholar   +1 more source

Neutralizing Activity of BNT162b2-Elicited Serum

New England Journal of Medicine, 2021
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first ide...
Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi   +17 more
openaire   +2 more sources